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Abstract 
 
While millions of individuals suffer concussions caused by head trauma each year, an accurate, 
reliable, and portable diagnostic for concussions does not yet exist, making a novel concussion 
detection system necessary. Matrix Metalloproteinase-9 (MMP-9) is a biomarker whose 
concentration in the blood increases after suffering a head injury. We designed a chimeric 
protein sensitive to MMP-9 and planned to compare it to a MMP-9 repressor system to detect the 
status of an individual’s condition from a blood sample. When MMP-9 is tested, the chimeric 
protein system will use β-lactamase to hydrolyze nitrocefin producing a brown color and the 
repressor system will produce GFP because MMP-9 cleaves off the repressor from pPROT 
allowing transcription to occur. The results of the MMP-9 sensitive chimeric repressor system 
showed that by adding MMP-9 there was an increase in GFP production.  
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Introduction 
What is a Concussion? 
Each year, approximately 1.6-3.8 million concussions occur in sports and recreational 
activities (Daneshvar et al. 2011) and many concussions are still not reported. A concussion is a 
“a complex pathophysiological process affecting the brain, induced by biomechanical forces” 
which can be caused by either direct or indirect impact to the head, face, neck or elsewhere 
leading to “rotational acceleration of the brain” (Tator 2013). After receiving a concussion there 
are multiple symptoms that can occur such as loss of consciousness or amnesia, behavioral 
changes, and cognitive and somatic symptoms. Many times these symptoms can be 
underreported by the person in question or it is difficult to gage how severe the symptoms are 
such as the severity of headaches and slowed reaction times (Daneshvar et al. 2011).  
Once a concussion has been received it is much easier to sustain another, and this 
phenomenon is called the second-impact syndrome (Tator 2013). Repeated concussions can 
cause chronic traumatic encephalopathy as well as negative long-term effects on the brain. These 
repeated injuries could lead to posttraumatic brain degeneration, which may cause dementia and 
movement disorders later in life (Tator 2013). Due to the probability of neurological damage 
caused by concussions, it is important to have accurate testing and management tools to diagnose 
concussions and keep those who suffer from concussions safe.  
 There are many types of concussions tests, which can be broken up into two large groups: 
assessment tools and management tools. Within these two groups there are physical examination 
tools, symptom checklists, sideline assessment tools, balance assessment tools, computerized 
neurocognitive testing and neuroimaging. Despite these tools, no test has been shown to quickly 
and reliably assess concussions in all cases. Further, they are costly and must be performed in a 
hospital or by trained specialists.  
Biomarkers 
The term “biomarker” refers to a broad category of medical signs that indicate the 
medical status of a patient, so these biomarkers can then be used as surrogate endpoints. In order 
for a molecule to be regarded as a biomarker for a disease, the molecule has to be able to provide 
accurate information to researchers and physicians to the presence of a disease (Strimbu 2010). 
An example of such a biomarker would be hemoglobin ions, which increase after an acute 
ischemic stroke. This increase can be used to detect acute ischemic strokes at a sensitivity level 
of 70.2% (Huang et. al. 2009) 
A study completed in 2015 revealed that the levels of several enzymes were increased in 
blood within hours of a concussion. One such enzyme is Matrix Metalloproteinase 9 (MMP-9), 
which was elevated 3.6-4.5 fold up to eight hours after head injuries (Rongzi et al. 2014). This 
finding raises the possibility that MMP-9 could be used as a biomarker for concussions.  
Matrix Metalloproteinase-9 
MMP-9 comes from a family of multi-domain proteins called Matrix Metalloproteinase 
(MMPs). MMPs generally function in the extracellular environment of cells by degrading both 
matrix and non-matrix proteins. These proteins play central roles in morphogenesis, wound 
healing, and in progression of diseases such as cancer and chronic tissue ulcers (Nagase et. al. 
2006). 
MMP-9 plays a vital role in the promotion of tumor growth during the early stages of 
tumorigenesis. MMP-9 is also known to regulate different pathological remodeling processes 
that involve inflammation. MMP-9 does this by degrading extracellular matrix proteins while 
activating cytokines and chemokines to regulate tissue remodeling (Yabluchanskiy et al. 2013). 
MMP-9 contains three fibronectin type II repeats with a high affinity for collagen. This draws the 
MMP-9 enzyme to the collagen, enhancing the rate of hydrolysis. MMP-9 cleaves many other 
proteins, and three different families of substances have been identified. The largest protein 
target family contains a Pro-X-X-hy-(Ser/Thr) motif where X is any residue and hy is a 
hydrophobic residue. The second group is defined as Gly-Leu-(Lys/Arg) motif, and the third 
family had all peptides cleaved after an Arg residue (Kridel et al. 2001). This emphasizes the 
vast diversity of protein targets cleaved by MMP-9 and the specificity of MMP-9’s cleavage 
sites.  
Chimeric Proteins 
 Chimeric proteins are a single protein product generated from the fusion of proteins or 
protein domains from several different proteins. Chimeric proteins can be created using a PCR 
procedure to combine multiple gene fragments. Some uses of chimeric proteins are to study the 
folding of a protein or to evaluate its stability (Tripathi et. al. 1999). Chimeric proteins have also 
been used in medical applications such as creating a fusion protein to increase the immune 
response to tumor cells in people with breast cancer (Grandori et. al. 1997).  
Project Goal 
Currently there are limited tests for accurately diagnosing concussions. MMP-9 is a 
demonstrated biomarker for concussions and could be an important factor in the development of 
new concussion diagnostics. Therefore, the goal of this project is to create an assay for detecting 
MMP-9 in blood samples, which can be used to evaluate whether someone is suffering from a 
concussion. We will build and test two different models for detecting MMP-9 activity. 
One method is to create a chimeric biosensor similar to the one created by Nirantar et al. 
This chimeric protein will be comprised of β-lactamase attached to its inhibitor, BLIP, by a 
linker containing the MMP-9 cleavage site (Nirantar et al. 2013). When MMP-9 cleaves this 
linker, BLIP will be separated from β-lactamase. β-lactamase can then hydrolyze nitrocefin 
resulting in a brown color. This color change will indicate an increase in MMP-9 in the blood 
and could therefore be used to evaluate if someone suffered a head injury (Figure 1).  
 
 
 
Figure 1: β-lactamase and BLIP held together by a protein linker containing a cleavage site for MMP-9 without (left side) 
and with (right side) MMP-9 present. When MMP-9 separates BLIP from β-Lactamase, nitrocefin with be hydrolyzed by 
the β-Lactamase, resulting in a brown color change.  
  
To understand how our chimeric protein system compares to other methods of detecting 
MMP-9, we will analyze the function of a previously designed MMP-9 sensor that utilizes an 
MMP-9 sensitive repressor to repress the expression of the reporter gene GFP (Pitt iGEM 2015, 
Figure 2). The chimeric repressor protein binds the pPROT promoter and inhibits the expression 
of GFP. The chimeric repressor contains an MMP-9 cleavage site, and will dissociate from the 
pPROT promoter upon MMP-9 cleavage. The removal of this inhibitor will allow for E. Coli 
RNA polymerase to bind to the pPROT resulting in the production of the GFP.  
 
 
 
 
Figure 2: pPROT is bound by a chimeric repressor that contains a cleavage site for MMP-9 and represses GFP expression 
in the absence of MMP-9 (left side). When MMP-9 is present, it cleaves the repressor and activates transcription from 
pPROT, and GFP is produced (right side). 
 
  
Methods 
Designing MMP-9 Sensitive Systems 
 
In order to design the chimeric protein system, A Plasmid Editor (ApE) was used to map 
out the specific DNA sequence. The MMP-9 sensitive chimeric protein that was designed 
contains β-lactamase, BLIP-Linker and pSB1C3, a plasmid backbone containing a gene that 
codes for chloramphenicol (CAM) resistance (Figure 3). 
 
 
 
 
Figure 3: Designed MMP-9 sensitive protein vector containing β-lactamase, BLIP-linker and PSB1C3, a gene that codes 
for chloramphenicol resistance  
The MMP-9 sensitive chimeric repressor system contains two vectors: one is the pPROT 
and GFP (Figure 4a) and the other is the pPROT repressor (Figure 4b). The plasmids were 
obtained from the 2015 Pitt iGEM team.  
 
 
 
 
 
 Figure 4: A) The pPROT promoter and the GFP gene along with chloramphenicol (CAM) resistance. B) The pPROT 
repressor and kanamycin (KAN) resistance 
 
Construction of β-lactamase 
 In order to construct the β-lactamase sequence, A Plasmid Editor (ApE) was used to map 
out the specific DNA sequence. The DNA sequence was derived from the experiment ran by 
Nirantar et. al. (Nirantar et. al. 2013). The sequence was taken from the pSB1A3 template 
obtained from the Registry of Standard Biological Parts (parts.igem.org). The β-lactamase 
sequence can be found in Appendix 1. The 3’ and 5’ primers for B-lactamase were both obtained 
from the Registry of Standard Biological Parts. The sequence of these primers can be found in 
Table 1. DNA sequencing and insert amplification was performed using the primers VF2 and VR 
(Table 1) as necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) B) 
  
Table 1: List of primers and the sequences used in this study 
Primer Name Primer Sequence 
3’ β-lactamase primer 
sequence 
ACGCTGCAGCGGCCGCTACTAGTGTAATGCTTAATCAG 
5’ β-lactamase primer 
sequence 
TCCTTCGAGAGAAAAAGGAAGAGTATGA 
BLIP-linker prefix 
sequence 
GTTTCTTCGAATTCGCGGCCGCTTCTAG 
BLIP-linker suffix sequence TAACTGCAGCGGCCGCTACTAGTA 
VF2 primer sequence TGCCACCTGACGTCTAAGAA 
VR primer sequence ATTACCGCCTTTGAGTGAGC 
 
Construction of BLIP-linker 
The BLIP-linker sequence was created similarly to the β-lactamase sequence both using 
ApE and deriving the sequence from the experiment by Nirantar et. al. (2013). The BLIP-linker 
sequence was synthesized by Integrated DNA Technologies (Coralville, Iowa) and the DNA 
sequence can be seen in Appendix 2.  The prefix and suffix sequences for BLIP-linker were also 
obtained from the Registry of Standard Biological Parts. The sequences for these primers can be 
found in Table 1.  
Plasmid 
 The plasmid backbone, pSB1C3, was ordered from the Registry of Standard Biological 
Parts and contained a strong constitutive promoter, J23119. Both the sequence for the pSB1C3 
backbone and the J23119 promoter can be found in Appendix 3.  
Cloning of β-lactamase and BLIP-linker into Biobrick plasmid 
 A PCR reaction was setup to create the BLIP-linker and β-lactamase. The β-lactamase 
reaction was set up using the 5’ and 3’ β-lactamase primers (10 µM), the pSB1A3 β-lactamase 
template (0.025 µM), PCR mastermix (New England Biolabs, 25µL), and water (21µL). The 
BLIP-linker reaction was set up using the 5’ and 3’ BioBrick primers (10 µM), the synthetic 
BLIP-linker template (0.025 µM), PCR mastermix (25µL), and water (21µL).  The PCR protocol 
can be found in Table 2. After the PCR reaction was complete, the inserts were purified using the 
PCR cleanup protocol (Macherey-Nagel). PCR products were digested with Xba1 and Pst1 in 
preparation for ligation, and confirmed by agarose gel electrophoresis.  
 
Table 2: PCR protocol to cut β-lactamase and BLIP-linker 
Temperature Time Number of Cycles 
95℃ 1 minute 1 
95℃ 30 seconds 30 
50℃ 45 seconds 30 
72℃ 1 minute 30  
72℃ 2 minutes 1 
 
Miniprep of plasmids was prepared using the Macherey-Nagel NucleoSpin Plasmid 
Miniprep Kit according to the manufacturer’s instructions. The pSB1C3 plasmid miniprep (50µL 
of 0.025µM) was prepared for ligation by digestion with Spe1 (1µL) and Pst1 (1µL) (New 
England BioLabs), and incubated in a 37℃ water bath overnight. The next day the digest was 
incubated at 80℃ for 10 minutes. 10µL of the cut plasmid, along with the undigested plasmid, 
underwent agarose gel electrophoresis to ensure that the restriction enzymes cut the plasmid 
properly. The β-lactamase insert miniprep (50µL) was then digested using Xba1 (1µL) and Pst1 
(1µL), and the digest was incubated in a 37℃ water bath overnight. A reaction cleanup 
(Macherey-Nagel) was completed and eluted in 30µl of water.  
The digest was then ligated and four water/insert combinations were tested. Each reaction 
had 2µL10x ligation buffer, 2µL purified pSB1C3 plasmid, and 1µL T4 DNA ligase. Different 
combinations of water and β-lactamase insert were used. The ligation reaction was incubated at 
room temperature for at least 1 hour.  
10µL of each ligation was transformed into E. coli strain DH5α cells. The cells with the 
ligation reaction were incubated on ice for 30 minutes, heat shocked at 42℃ for 1 minute, and 
then on ice for 5 minutes. 200µL of LB media was added to each transformation and incubated at 
37℃ for 2 hours in a shaker. After 2 hours, 200µL of each transformation was plated onto LB 
Agar + CAM (33 µg/mL) petri plates and incubated overnight at 37℃.  
10µL of water was added to 11 PCR tubes and a single colony was resuspended in each. 
The colonies were re-streaked on a new LB Agar + CAM plates. Then in a new PCR strip, PCR 
mastermix (12.5µL), 10µM primer VF2 (1.25µL), 10µM primer VR (1.25µL), and the 10µL of 
water/ bacteria mix was mixed together. The sequences for the VF2 and VR primers can be 
found in Table 1. A PCR reaction was runfor these 11 tubes following the PCR protocol found in 
Table 3. Each of the reactions was confirmed by agarose gel electrophoresis for the presence of 
the β-lactamase insert.  
 
Table 3: PCR colony protocol to check for the β-lactamase insert 
Temperature Time Number of Cycles 
95℃ 2 minute 1 
95℃ 30 seconds 33 
55℃ 45 seconds 33 
72℃ 1 minute 33 
72℃ 2 minutes 1 
   
Transformation of pPROT and MMP-9 repressor 
 The pPROT-GFP reporter and MMP-9 repressor were generously gifted to us by the Pitt 
2015 iGEM team, and transformed into competent cells following the iGEM transformation 
protocol with a few minor changes (Transformation Protocol n.d.). These changes were that step 
4 was not performed and in step 10, only 200µL of each transformation were plated on 
chloramphenicol (cam) plates. The following day single colonies from the pPROT-GFP plate 
were picked and suspended in 5mL of LB media that grew overnight and minipreps were 
completed.  
The repressor vector was moved into a kanamycin (KAN) resistant pSB1K3.m1 plasmid 
backbone. Both the original repressor vector (CAMR) and KAN vector were each digested with 
Ecor1 (1µL) and Pst1 (1µL), and incubated overnight in a 37℃ water bath overnight. A PCR 
cleanup (Macherey-Nagel) was completed for the KAN vector and the vector was eluted in 30µl 
of water. 2µL of Shrimp Alkaline Phosphatase (SAP) was added to the repressor vector , 
incubated at 37℃ for 20 minutes and then incubated at 80℃ for 10 minutes. The digests were 
then ligated and four water/repressor combinations were tested. Each reaction had 2µL10x 
ligation buffer, 2µL purified KAN plasmid, and 1µL T4 DNA ligase. The ligations were 
transformed into competent cells and plated onto KAN plates. The following day, single colonies 
were picked and suspended in 5mL of LB media that grew overnight and minipreps were 
completed.  
The repressor and pPROT-GFP minipreps were co-transformed into competent cells. Six 
colonies were picked for overnight cultures to be miniprepped the following day. A mini digest 
was completed in order to check for the pPROT and the MMP-9 repressor. All six colonies 
contained the correct bands sizes of 889 base pairs for pPROT and 757 base pairs for the 
repressor. As controls two other transformations were completed with the pPROT and the 
J23119 empty vector and the repressor and the pSB1K3.m1 vector.  
Chimeric Repressor Assay 
Sensor extract was prepared according to the protocol created by the Pittsburgh iGEM 
2015 team (iGEM 2015) with the following changes: SE RB buffer was used in place of SE WB 
buffer; the cells were never stored in liquid nitrogen or kept frozen at -80℃ but were used 
immediately after harvest; the cells were lysed using 30 strokes in a dounce homogenizer with 
Teflon pestle instead of sonication; lysates were not dialyzed; SE PB buffer was not used, and 
instead assays below were performed in SE RB buffer.   
 To assess the effectiveness of the sensor extract in detecting MMP-9, an assay was 
designed that involved monitoring the fluorescence of each culture with or without the presence 
of MMP-9. This assay was performed by pipetting eight samples of cell lysates, 200µL per 
sample, into wells of an opaque white 96-well plate: one pair with only the pPROT vector, one 
pair with only the repressor vector and two pairs with both vectors. 1µL of 0.2µM of 
recombinant human MMP-9 (SINO Biologicals) was added to one 200µL sample of lysate from 
each pair and the lysates were incubated at 32℃ for 90 minutes. Samples were then transferred to 
a 96 well plate and a plate reader (Perkin-Elmer LS 55 Luminescence Spectrometer) was used to 
assess the fluorescence values of each sample at an excitation wavelength of 485nm and 
emission wavelength of 515nm. 
 
Microscopy 
Cultures containing the pPROT-GFP reporter and/or repressor were viewed on a Zeiss AXIO 
observer A1 fluorescence microscope. Images of the cells were taken using New Window Idea 
5Mp Color Mosaic SPOT supported camera and processed using SPOT Basic software 
(Diagnostic Instruments, Inc.).    
Results  
The overall goals of this project were to design a chimeric protein MMP-9 sensitive 
detection system and compare it to an existing chimeric repressor MMP-9 detection system. 
Multiple attempts were made to clone the chimeric β–lactamase-BLIP protein (Figure 3) and 
transform it into DH5α competent cells. Some of these attempts included cloning each individual 
part of the vector, β-lactamase and BLIP-linker, into different vectors and either cloning the β-
lactamase sequence into the vector first or cloning the BLIP-linker sequence into the vector first. 
Unfortunately, due to time constraints and technical issues, the chimeric protein assay has yet to 
be created. Therefore, we shifted our focus to the characterization of the chimeric repressor 
system. 
We began by determining the effectiveness of the pPROT promoter and repressor system. 
Five cultures were grown overnight: repressor only, pPROT-GFP only, and three colonies of 
repressor plus pPROT-GFP. The day of the testing, the optical density (OD) was taken in order 
to dilute each culture to the same number of cells. The fluorescence values for each of the 
cultures at varying dilutions can be seen in Figure 5a. In the undiluted sample, the fluorescence 
of the culture expressing pPROT-GFP without the repressor was outside the machine's dynamic 
range of 0-1000, but the other samples all had similar background levels of fluorescence. At the 
1:200 dilution all cultures could be compared. As seen in Figure 5a, the repressor and the three 
repressor plus pPROT-GFP cultures were all around a fluorescence of 100 arbitrary units (a.u.) 
while the pPROT-GFP only culture was around 250 a.u. This demonstrates that the co-
transformation was successful and the repressor is indeed binding to pPROT and decreasing the 
expression of GFP as expected.  
In addition to measuring fluorescence using a plate reader, a fluorescence microscope 
was used to take pictures of a sample of each of the cultures (Figure 5b). These images also show 
that the repressor is limiting the expression of GFP in the pPROT-GFP plus repressor samples. 
As seen in the images there is a high amount of GFP expression in the pPROT-GFP only sample 
compared to the repressor culture and repressor and GFP cultures.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A) GFP fluorescence (a.u.) of Repressor, GFP, and GFP+Repressor cultures at varying dilutions. B) Images of 
cell cultures under a fluorescent microscope at 400X magnification. 
 
Next, we sought to determine whether the addition of MMP-9 to this system would 
cleave the repressor protein and result in the expression of GFP. MMP-9 is not membrane-
permeable, thus we made lysates from the cell cultures expressing each of the plasmid 
combinations described previously.  
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Figure 3: Fluorescence values of cell lysates containing pProt repressor (Repressor), pProt promoter + GFP, or both 
vectors (GFP + Repressor). All four lysates either received (+) or did not receive (-) MMP-9. A sample of SE RB buffer 
was used as a negative control (Blank). 
 
 As seen in Figure 6, the fluorescence values of the lysates containing only the repressor 
showed no difference whether or not MMP-9 was added to the lysate. In fact, the fluorescence 
values were very similar to that of the blank (only SE RB buffer). The fluorescence values of the 
lysates only containing pPROT-GFP were off scale in both cases as the plate reader used had a 
dynamic range of 0-1000 a.u. and the amount of fluorescence produced by the GFP-containing 
lysates were more than 1000 a.u. The pPROT-GFP plus repressor containing lysates produced 
more fluorescence than the repressor alone, indicating a background level of GFP expression 
even when the repressor is intact. However, we observed a slight increase of approximately 5-7% 
in GFP expression in two different lysate samples that contained MMP-9. This outcome suggests 
that the MMP-9 is cleaving the repressor, causing the repressor to separate away from the 
pPROT-GFP vector, which results in GFP production in the sample. Due to time constraints, this 
assay could not be repeated, thus statistical analyses could not be performed.   
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Discussion  
The overall goals of this project were to design a MMP-9 sensitive chimeric protein 
detection system and compare it to an existing MMP-9 chimeric repressor detection system. It 
was hypothesized that the MMP-9 sensitive chimeric protein system would be a more robust 
reported of MMP-9 activity than the MMP-9 sensitive chimeric repressor system. This is because 
in order to test the effectiveness of the MMP-9 repressor system, it is necessary to produce a cell 
lysate capable of in vitro transcription and translation of the GFP reporter. The chimeric protein 
detector system would create a protein product which could be more easily activated without in 
vitro transcription or translation. Further, the chimeric protein could be purified from the bacteria 
and used to develop the assay into a portable on-site diagnostic.  
 To achieve our project goals, a chimeric protein vector was designed. Even after multiple 
attempts at cloning, the MMP-9 sensitive chimeric protein has yet to be properly cloned. We 
hypothesize that the intermediate cloning products are interfering with the transformation. To 
avoid this problem, instead of cloning separate pieces together, the final gene product could be 
created by gene synthesis. This may be a more efficient method of creating this chimeric 
construct.  
 As can be seen from the results of the chimeric repressor assay (Figure 6), MMP-9 causes 
a detectable difference in the GFP levels in cell lysates containing the pPROT promoter and the 
repressor. Although the change in the overall fluorescence was detectable, it was not as drastic 
between samples of lysates containing pPROT and repressor and samples of lysates containing 
pPROT, repressor and MMP-9. Due to time constraints as this assay was only able to be run 
once so, optimal testing conditions for MMP-9 were not yet determined. Also, no ATP was used 
during the assay, which could have caused less GFP to be produced. If this assay was optimized, 
it could be used as an effective tool to detect concussions 
 Once the assay has been optimized, in order for it to be an effective diagnostic tool the 
assay needs to be made portable and easy to use. It may be possible to create a concussion 
detection kit so that, after someone suffers a head injury, their blood sample may be taken. Then 
either the chimeric protein sensor system or the chimeric repressor sensor system may be used in 
order to quickly determine if someone has a concussion. In the future this system may be used as 
a quick, effective diagnostic tool in order to determine a concussion. 
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Appendix 
Appendix A: β-lactamase sequence from pSB1A3 template  
 
GCCGAATTCGCGGCCGCTTCTAGATGGAAAAAGGAAGAGTATGAGTATTCAACATT
TCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCA
GAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTA
TATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACG
TTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATT
GACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTT
GAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT
ATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAAC
GATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAA
CTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGT
GACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGA
ACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGT
TGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCT
GGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACG
AAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTACTAGTAGCGGC
CGCTGCAGGCC 
 
Appendix B: BLIP-linker sequence 
 
GCTGAATTCGCGGCCGCTTCTAGAGGTGGCCCACTGTTCTATAGCGTCGGCAAAATTCCGCGTACACT
GACGGGTGGGCGCCTGCGCCGCCTGGTGACCGCGGCGCTGCTTGCCGCTACCATGGCCGGAAGCACTG
CGGCCGTGGCTCTGGCGGCACCGAAAACCGATCCGGACGAAAATTATTTGACTGACACAAAATATCAG
GCTATCTCATTTGGTATGAGCCGTCAACAAGTGGCGGCGGTTATTGGCACTCGCCCGCATTGTTCCGGT
ACCGGTAGTGACGGCCCGTTGGTTTGTTGGGCGAAAAACCAATTTGCCGATCAAACAGGCTCGTTTAC
CTTTAATGCCGCCGATCAGTTAACCCGCAAAGAGAAGGATTATGCCTTTGCTTATGCATGGTATACTCG
CGATTTACCGATGACCATGACCAAGGCCCAATATGAACAGCAATTCACAGTAGGAGACACCCTTGCAG
AAGTGAACGCCCGTGTCGCTGGTACGGCGTGCACCGATCGCTGGGTGGAATATCCGGGTTACCCATCT
CCATCGGGTTGGAAAACGATGATCCAATGCACCGGAACGGTCTCTGAAGCATACCCGGATATTGAGTT
CCATTTCACGGACGGCGTACTCACGCACAAAACATATTATTCGCGCAATGATCCGCACTGATAACCAG
GCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGA
ACGCTCTCTACTAGAGTCACACTGGCTCACCTTCGGGTGGGCCTTTCTGCGTTTATATACTAGTAGCGG
CCGCTGCAGCGT 
 
 
 
 
 
 
 
 
 
 
Appendix C: pSB1C3 backbone sequence and J23119 promoter sequence 
 
PSB1C3 sequence: 
TACTAGTAGCGGCCGCTGCAGTCCGGCAAAAAAGGGCAAGGTGTCACCACCCTGCC
CTTTTTCTTTAAAACCGAAAAGATTACTTCGCGTTATGCAGGCTTCCTCGCTCACTGA
CTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGT
AATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAA
GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCACAG
GCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA
ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCT
CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG
CGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGC
TCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCC
GGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCA
GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT
GAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCT
GCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAA
CCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAA
AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACG
AAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA
TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTT
GGTCTGACAGCTCGAGGCTTGGATTCTCACCAATAAAAAACGCCCGGCGGCAACCG
AGCGTTCTGAACAAATCCAGATGGAGTTCTGAGGTCATTACTGGATCTATCAACAGG
AGTCCAAGCGAGCTCGATATCAAATTACGCCCCGCCCTGCCACTCATCGCAGTACTG
TTGTAATTCATTAAGCATTCTGCCGACATGGAAGCCATCACAAACGGCATGATGAAC
CTGAATCGCCAGCGGCATCAGCACCTTGTCGCCTTGCGTATAATATTTGCCCATGGT
GAAAACGGGGGCGAAGAAGTTGTCCATATTGGCCACGTTTAAATCAAAACTGGTGA
AACTCACCCAGGGATTGGCTGAGACGAAAAACATATTCTCAATAAACCCTTTAGGG
AAATAGGCCAGGTTTTCACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAAC
TGCCGGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGCTCA
TGGAAAACGGTGTAACAAGGGTGAACACTATCCCATATCACCAGCTCACCGTCTTTC
ATTGCCATACGAAATTCCGGATGAGCATTCATCAGGCGGGCAAGAATGTGAATAAA
GGCCGGATAAAACTTGTGCTTATTTTTCTTTACGGTCTTTAAAAAGGCCGTAATATCC
AGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAATGT
TCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTCCA
TTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTAGTG
ATCTTATTTCATTATGGTGAAAGTTGGAACCTCTTACGTGCCCGATCAACTCGAGTG
CCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGT
ATCACGAGGCAGAATTTCAGATAAAAAAAATCCTTAGCTTTCGCTAAGGATGATTTC
TGGAATTCGCGGCCGCTTCTAGAG 
 
J23119 sequence: 
TTGACAGCTAGCTCAGTCCTAGGTATAATGCTAGC  
